全球毒理学检测外包市场规模、份额、趋势和成长分析报告（2026-2034年）

预计毒性测试外包市场将从 2025 年的 45.6 亿美元成长到 2034 年的 107.7 亿美元，2026 年至 2034 年的复合年增长率为 10.03%。

随着製药、生物技术、农业化学品和特种化学品公司越来越依赖受託研究机构(CRO) 进行符合良好实验室规范 (GLP) 的非临床安全性测试，毒性测试外包市场正经历显着成长。生物製剂、细胞和基因疗法以及新型小分子化合物的开发平臺不断扩展，推动了对涵盖体外、体内和计算方法的综合毒理学检测服务的需求。 CRO 在设备容量和方法多样性方面的投入，使申办方能够有效地降低早期研发阶段的风险。

关键成长要素包括製药和生物技术产业研发投入的增加、人体临床试验监管安全要求的日益严格，以及新型治疗方法的复杂性不断提高，需要专门的检测技术。高通量体外检测、晶片器官模型和预测性计算毒理学的进步，透过缩短试验週期和提高转化预测的准确性，提升了合约研究组织（CRO）的提案。儘管成本压力和对可预测试验进度的需求推动了外包，但CRO之间的策略联盟和併购正在扩大其全球服务覆盖范围。

前景依然强劲。随着新型疗法和生物製药鼓励采用减少动物使用的替代方法，市场需求将会增加。投资于人工智慧驱动的风险评估、转换模型和监管咨询的合约研究组织（CRO）将脱颖而出。区域产能扩张，尤其是在亚洲，将带来成本和进度优势，而从药物发现到首次人体临床试验的一体化服务将吸引寻求单一合作伙伴解决方案的申办者。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球毒理学检测外包市场：依方法划分

• 市场分析、洞察与预测
• In Vitro
• In Vivo

第五章：全球毒理学检测外包市场：依GLP类型划分

• 市场分析、洞察与预测
• GLP
• 非GLP规范

第六章：全球毒理学检测外包市场：依最终用途划分

• 市场分析、洞察与预测
• 製药和生物製药公司
• 学术研究机构
• 其他的

第七章 全球毒理学检测外包市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 亚太其他地区
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Eurofins Scientific
  • SGS SA
  • Charles River Laboratories
  • Thermo Fisher Scientific Inc
  • Intertek Group Plc
  • Catalent Inc
  • ICON Plc
  • Medpace
  • Wuxi AppTec
  • Labcorp Drug Development

The Toxicity Testing Outsourcing Market size is expected to reach USD 10.77 Billion in 2034 from USD 4.56 Billion (2025) growing at a CAGR of 10.03% during 2026-2034.

The toxicity testing outsourcing market has grown substantially as pharmaceutical, biotech, agrochemical, and specialty chemical companies increasingly rely on contract research organizations (CROs) for GLP-compliant preclinical safety studies. Rising R&D pipelines-driven by biologics, cell and gene therapies, and novel small molecules-have expanded demand for comprehensive toxicology packages spanning in vitro, in vivo, and computational methods. CRO investments in capacity and assay diversity enabled sponsors to de-risk early stage development efficiently.

Key growth drivers include escalating R&D spend across pharma and biotech, stringent regulatory safety requirements for human trials, and the complexity of new therapeutic modalities that require specialized testing expertise. Advances in high-throughput in vitro assays, organ-on-chip models, and predictive computational toxicology increase CRO value propositions by shortening timelines and improving translational predictivity. Cost pressures and the need for predictable study timelines encourage outsourcing, while strategic partnerships and M&A among CROs expand global service footprints.

Future prospects are strong: demand will rise as novel therapeutics and biologics require deeper safety characterization, and as regulators incentivize alternative methods that reduce animal use. CROs that invest in AI-driven risk assessment, translational models, and regulatory consulting will differentiate. Regional capacity expansion-notably in Asia-offers cost and timeline advantages, and integrated service offerings (discovery-to-first-in-human) will attract sponsors seeking single-partner solutions.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Method

• In Vitro
• In Vivo

By GLP Type

• GLP
• Non GLP

By End-Use

• Pharmaceutical And Biopharmaceutical Companies
• Academic And Research Institutes
• Others

COMPANIES PROFILED

• Eurofins Scientific, SGS SA, Charles River Laboratories, Thermo Fisher Scientific Inc, Intertek Group plc, Catalent Inc, ICON plc, Medpace, Wuxi AppTec, Labcorp Drug Development
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL TOXICITY TESTING OUTSOURCING MARKET: BY METHOD 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Method
• 4.2. In Vitro Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. In Vivo Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL TOXICITY TESTING OUTSOURCING MARKET: BY GLP TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Glp Type
• 5.2. GLP Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Non GLP Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL TOXICITY TESTING OUTSOURCING MARKET: BY END-USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-use
• 6.2. Pharmaceutical And Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Academic And Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL TOXICITY TESTING OUTSOURCING MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Method
  • 7.2.2 By Glp Type
  • 7.2.3 By End-use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Method
  • 7.3.2 By Glp Type
  • 7.3.3 By End-use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Method
  • 7.4.2 By Glp Type
  • 7.4.3 By End-use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Method
  • 7.5.2 By Glp Type
  • 7.5.3 By End-use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Method
  • 7.6.2 By Glp Type
  • 7.6.3 By End-use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL TOXICITY TESTING OUTSOURCING INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Eurofins Scientific
  • 9.2.2 SGS SA
  • 9.2.3 Charles River Laboratories
  • 9.2.4 Thermo Fisher Scientific Inc
  • 9.2.5 Intertek Group Plc
  • 9.2.6 Catalent Inc
  • 9.2.7 ICON Plc
  • 9.2.8 Medpace
  • 9.2.9 Wuxi AppTec
  • 9.2.10 Labcorp Drug Development